Expanding Treatment Options with Novel Agents in HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Speakers: Yelana Janjigian, MD, Chief, Gastrointestinal Oncology ServiceEric Van Cutsem, MD, PhD, Gastroenterology / Digestive Oncology
Duration: 120 minutes
Presented on: December 8, 2021
CME InformationExpanding Treatment Options with Novel Agentsin HER2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaJointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the American Gastroenterological Association Inc (AGA).
ACKNOWLEDGEMENTSupported by educational grants from AstraZeneca, Daiichi Sankyo, and Merck.
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
ENDURING CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this internet enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION
Enduring MaterialDecember 8, 2021 – December 8, 2022.
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
- Discuss the significance of HER2 molecular testing in the management of patients with gastric and GEJ cancer
- Assess the current management strategy for patients with HER2+ gastric and GEJ cancer
- Evaluate efficacy data from practice-changing clinical trials on first-line and next-line therapy for trastuzumab-resistant gastric and GEJ cancer
- Review strategies to mitigate adverse effects of ICIs and ADCs and optimize management of patients with HER2+, trastuzumab-resistant gastric and GEJ cancer
TARGET AUDIENCEThe intended audience for this activity program are medical oncologists, GI oncologists, gastroenterologists, surgeons, pathologists, oncology nurses, nurse practitioners, physician assistants, oncology pharmacists, and other clinicians involved in the management of patients with gastric or GEJ cancer.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 2 hours to complete.
METHOD OF PARTICIPATIONThere are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTERESTPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Yelena Y. Janjigian, MD
Associate Attending Physician
Associate Professor, WCMC
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Consultant/Independent Contractor: AstraZeneca, Basilea Pharmaceutica, Bristol-Myers Squibb, Merck Serono, RGENIX, Eli Lilly, Daiichi Sankyo, Pfizer, Bayer, Imugene, Merck, Zymeworks Inc., Seagen, Michael J. Hennessy Associates, Paradigm Medical Communications
Grant/Research Support: NCI, Department of Defense, Cycle For Survival, Fred’s team, RGENIX, Bayer, Genentech/Roche, Bristol Myers Squibb, Eli Lilly , Merck
Eric Van Cutsem, MD, PhD
Professor of Gastroenterology / Digestive Oncology
University Hospitals Gasthuisberg / Leuven & KULeuven
Advisor/Consultant: Abbvie, Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Halozyme, GSK, Helsinn, Incyte, Ipsen, Janssen Research, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Pierre Fabre, Roche, Seattle Genetics, Servier, Sirtex, Terumo, Taiho, TRIGR, Zymeworks
Research Grant/Funding (Institution): Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Tariqa Ackbarali
PlatformQ Health Education, LLC
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: Please contact the Postgraduate Institute for Medicine at email@example.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com at 1-877-394-1306 or at Info@OMedLive.com.